Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics
Open Pre-Solicitation Posted
- Solicitation number
- 75N98027R00020
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Place of performance
- Bethesda, Maryland, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
NIH's National Center for Advancing Translational Sciences (NCATS) Therapeutic Development Branch is seeking sources for a potential requirement for reagent generation supporting bioanalytical method development on biologic therapeutics, with responses due November 30, 2026, at 11:00 a.m. Eastern Time. This is a sources sought notice, not a solicitation, and no award will be made from it. The Government will not reimburse respondent costs. No set-aside is used, but the Government is especially interested in small business sources, including 8(a), HUBZone, service-disabled veteran-owned, veteran-owned, woman-owned, and small disadvantaged businesses, to determine whether a set-aside is possible.
The potential vehicle is a 10-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract with task order award capability. Work includes generating and delivering polyclonal and monoclonal anti-drug antibodies (ADAs) with high affinity and specificity for novel biologic drugs in plasma/serum, tissue homogenates, and other biological matrices, including neutralizing antibodies (nAbs) against active epitopes. For gene-based therapies, scope includes antibodies against gene-of-interest proteins and carriers such as vector capsids. Purified antibodies are required at an estimated 10-50 mg scale per reagent.
Contractors must demonstrate capability in contract administration, project management, quality management compliance with FDA cGMP, GLP, GCP, ICH, and ISO regulations, facilities and equipment management, data access and technology transfer, and research involving live vertebrate animals. The notice cites NAICS 325411 and PSC AN11.
Capability statements must be emailed to polina.klimenkova@nih.gov, referencing sources sought notice number 75N98027R00020.
Notice text
Title: Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics
This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement.
This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only.
The Government is especially interested in determining (1) the availability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition (5) commercial product and services availability. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible.
Background: The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) conducts translational research in the area of human therapeutics development by moving small molecule and biologic drug candidates forward in the drug development pipeline. Upon reaching predetermined milestones, TDB hands off clinical candidates to external partners to bring these novel therapies to patients. In addition to developing new candidate drugs, TDB seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial preclinical stage of drug development. The TDB model is to operate as a comprehensive small molecule and biologics drug development organization, moving therapeutic candidates through each phase of the preclinical development process until an Investigational New Drug (IND) application is filed with the US Food and Drug Administration (FDA). TDB conducts drug development as collaborations, with therapeutic candidates originating from academia, industry, non- profit foundations, or internally from NCATS and other NIH Institutes and Centers. TDB’s operational strategy is to combine the capabilities of in-house staff and collaborative partners with complementary support from contract research organizations (CROs). Each development program operates in a multi-disciplinary matrix team environment, with NCATS responsible for the overall planning and execution.
Please see the attachment for more details.
Files
| File | Type | Posted |
|---|---|---|
| 75N98027R00020_TRND 6 Sources Sought Notice.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity